



Modeling the influence of circadian rhythms on the acute inflammatory response

Jeremy D. Scheff^a, Steve E. Calvano^b, Stephen F. Lowry^b, Ioannis P. Androulakis^{a,b,c,*}

^a Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA

^b Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, Clinical Academic Building, 125 Patterson Street, New Brunswick, NJ 08901, USA

^c Department of Chemical and Biochemical Engineering, Rutgers University, 98 Brett Road, Piscataway, NJ 08854, USA

ARTICLE INFO

Article history:

Received 13 January 2010

Received in revised form

8 March 2010

Accepted 16 March 2010

Available online 20 March 2010

Keywords:

Systems biology

Inflammation

PK/PD modeling

Signaling and regulation

Circadian rhythms

ABSTRACT

A wide variety of modeling techniques have been applied towards understanding inflammation. These models have broad potential applications, from optimizing clinical trials to improving clinical care. Models have been developed to study specific systems and diseases, but the effect of circadian rhythms on the inflammatory response has not been modeled. Circadian rhythms are normal biological variations obeying the 24-h light/dark cycle and have been shown to play a critical role in the treatment and progression of many diseases. Several of the key components of the inflammatory response, including cytokines and hormones, have been observed to undergo significant diurnal variations in plasma concentration. It is hypothesized that these diurnal rhythms are entrained by the cyclic production of the hormones cortisol and melatonin, as stimulated by the central clock in the suprachiasmatic nucleus. Based on this hypothesis, a mathematical model of the interplay between inflammation and circadian rhythms is developed. The model is validated by its ability to reproduce diverse sets of experimental data and clinical observations concerning the temporal sensitivity of the inflammatory response.

© 2010 Published by Elsevier Ltd.

1. Introduction

The acute inflammatory response is a critical component of the body's defense against a variety of harmful stimuli, such as an invading pathogen or trauma. Inflammation consists of a complex, coordinated set of interactions between the immune system and the neuroendocrine system to initiate the restoration of homeostasis, either through the removal of the pathogen or the repair of damaged tissue. Typically, inflammation is tightly regulated, activating when necessary and abating after healing has been initiated. However, inflammation does not always resolve appropriately; in some cases, a heightened level of inflammation persists, which can damage healthy tissue. Prolonged systemic inflammation comes with severe consequences, often leading to organ failure and death. This type of overwhelming inflammatory when accompanied by an infection is called sepsis. There are approximately 750,000 cases of severe sepsis every year in the United States alone, leading to over 200,000 deaths annually

(Angus et al., 2001). Thus, the management of inflammation is a major challenge in the treatment of critically ill patients.

Despite our understanding of the importance of this problem and extensive research towards the development of effective therapies, current treatment options (Annane et al., 2002; Bernard et al., 2001) remain limited and other novel therapies remain elusive (Freeman and Natanson, 2000). This is likely due to the inherent challenges in applying reductionist techniques to non-linear systems (Seely and Christou, 2000). In fact, it may be impossible to predict the outcome of perturbing a pathway involved in inflammation given only a knowledge of its isolated behavior (Vodovotz et al., 2004). For this reason, there is interest in applying techniques from systems biology towards the development of models of inflammation, with the goal of attaining a systems-level understanding of the key interactions in the inflammatory response.

In recent years, a number of models have been developed by applying different modeling techniques (agent based modeling or equation based modeling), at different scales (molecular, cellular, systemic, or a combination), and focusing on different specific problems (acute inflammation, trauma, or the response to a specific disease) (An, 2008; Foteinou et al., 2009c; Jit et al., 2005; Kumar et al., 2008; Li et al., 2008; Lipniacki et al., 2006; Mi et al., 2007; Prince et al., 2006; Zuev et al., 2006). These models have been developed with the practical goals of impacting healthcare

* Corresponding author at: Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA, Tel.: +1 732 445 4500x6212; fax: +1 732 445 3753.

E-mail addresses: jdscheff@eden.rutgers.edu (J.D. Scheff), calvanst@umdnj.edu (S.E. Calvano), lowrysf@umdnj.edu (S.F. Lowry), yannis@rci.rutgers.edu (I.P. Androulakis).

through translational systems biology (Foteinou et al., 2009d; Vodovotz et al., 2008) and rationalizing the design of experiments and clinical trials (Clermont et al., 2004). Because of the large number of components involved in inflammation, existing models make assumptions about which interactions are most important, either by simplifying or neglecting certain elements. One aspect that has not previously been studied from the perspective of systems biology is the interplay between circadian rhythms and inflammation.

Circadian rhythms are periodic processes that are synchronized to the 24 h light/dark cycle. This rhythmicity is widely observed in humans from the scale of biochemical reactions, such as hormone production, to behavioral patterns, such as regular sleeping and feeding times. In the context of healthcare, mouse and rat models have shown that the same dose of a drug can be lethal at certain times and ineffective at others (Levi and Schibler, 2007). Thus, it is not surprising that there is also a circadian component to inflammation; in fact, many of the elements typically included in models of inflammation (leukocytes, cytokines, and hormones) are known to have strong diurnal patterns (Coogan and Wyse, 2008). The importance of these variations is apparent by observing that sepsis patients have a heightened risk of mortality between 2 am and 6 am (Hrushesky et al., 1994).

This paper presents a mathematical model of the interplay between circadian rhythms in inflammation that synthesizes disparate biological knowledge about these systems. Circadian variability is introduced into our previous multiscale model of inflammation (Foteinou et al. in press) under the hypothesis that the observed circadian variations in the inflammatory response are governed by the hormones cortisol and melatonin and their interactions with immune cells. The model is validated by its ability to reproduce experimental results from a variety of sources and its qualitatively accurate predictions of diurnal variability in the strength of the inflammatory response.

2. Model

2.1. Modeling inflammation

In vivo human endotoxin challenge is a commonly used model for studying acute inflammation because it evokes signs and symptoms of systemic inflammation along with significant transcriptional and neuroendocrine responses (Lowry, 2005). Lipopolysaccharides (LPS, endotoxin), found in the outer membrane of gram-negative bacteria are pathogen-associated molecular patterns (PAMPs) that are recognized by innate immune system pattern recognition receptors (PRRs), most notably Toll-like receptor 4 (TLR4), thus eliciting an inflammatory response. Based on data generated from the human endotoxemia model, we have previously developed a semi-mechanistic mathematical model of human endotoxemia (Foteinou et al. in press; Foteinou et al., 2009a; Foteinou et al., 2009b; Foteinou et al., 2009c). These previous efforts are based on three critical concepts: (1) essential transcriptional dynamics are computationally discovered through the analysis of gene expression data (Yang et al., 2009); (2) physicochemical modeling (Aldridge et al., 2006) is used to model the signaling cascades that lead to the transcriptional responses; and (3) indirect response (IDR) (Jusko and Ko, 1994) modeling is used to represent the implicit relationships between model components.

The binding of LPS to its receptor TLR4 (*R*) (Eq. (1a–d)) leads to the activation of the NF-κB, which initiates the transcriptional response to inflammation. NF-κB is normally sequestered in the cytoplasm in an inactive form when it is bound to its

inhibitor IκBα. LPS stimulates the activation of IKK, which initiates the degradation of IκBα. Then, NF-κB can move into the nucleus where it regulates the transcription of a number of genes, including its inhibitor IκBα, creating a negative feedback loop. The NF-κB module is based on a reduced model of NF-κB dynamics that includes IKK (Eq. (1e)), nuclear (activated) NF-κB (Eq. (1f)), and IκBα (Eq. (1g) and (1h)) (Ihekweba et al., 2004). The fundamental transcriptional processes found in the gene expression data are the pro-inflammatory response (Eq. (1i)), the anti-inflammatory response (Eq. (1j)), and the energetic response (Eq. (1k)).

$$\frac{dLPS}{dt} = k_{lps,1}LPS(1-LPS) - k_{lps,2}LPS \quad (1a)$$

$$\frac{dR}{dt} = k_{syn}mRNA_R + k_2(LPSR) - k_1LPSR - k_{syn}R \quad (1b)$$

$$\frac{d(LPSR)}{dt} = k_1LPSR - k_3(LPSR) - k_2(LPSR) \quad (1c)$$

$$\frac{d(mRNA_R)}{dt} = k_{in,mRNA,R}(1 + H_{mRNA,R,P}) - k_{out,mRNA,R}mRNA_R \quad (1d)$$

$$\frac{dIKK}{dt} = k_3(LPSR)/(1 + IkBa) - k_4IKK + P \left(\frac{IKK^2}{1 + IKK^2} \right) \quad (1e)$$

$$\frac{dNFkBn}{dt} = \frac{k_{NFkB,1}IKK(1 - NFkBn)}{(1 + IkBa)} - k_{NFkB,2}NFkBnIkBa \quad (1f)$$

$$\frac{dmRNA_{IkBa}}{dt} = k_{in,IkBa}(1 + k_{IkBa,1}NFkBn) - k_{out,IkBa}mRNA_{IkBa} \quad (1g)$$

$$\frac{dIkBa}{dt} = k_{i,1}mRNA_{IkBa} - k_{i,2}(1 + IKK)(1 - NFkBn)IkBa - k_{i,1} \quad (1h)$$

$$\frac{dP}{dt} = k_{in,P}(1 + H_{P,NFkBn})(1 + H_{P,E})/A - k_{out,P}P \quad (1i)$$

$$\frac{dA}{dt} = k_{in,A}(1 + H_{A,CAMP})(1 + k_{A,FRN}FR(N))(1 + H_{A,E}) - k_{out,A}A \quad (1j)$$

$$\frac{dE}{dt} = k_{in,E}(1 + H_{E,P})/A - k_{out,E}E \quad (1k)$$

$$H_{i,j} = k_{i,j}I$$

The interplay between the NF-κB pathway and the pro- and anti-inflammatory responses normally leads to a healthy inflammatory response that resolves after LPS has been cleared, but high doses of LPS can lead to a state of persistent inflammation. In addition, NF-κB is regulated by glucocorticoids, both endogenous (cortisol (*F*)) and exogenous, which allows for the ability to assess potential treatment options. This is modeled by equations governing the inflammation-induced production of cortisol Eq. (1l) and its receptor Eq. (1m) and (1n) and the intracellular dynamics as the signal is transduced from the cytoplasm (Eq. (1o)) to the nucleus (E1. (1p)).

$$\frac{dF}{dt} = k_{in,Fen}(1 + H_{Fen,P}) - k_{out,F}F \quad (1l)$$

$$\frac{dR_m}{dt} = k_{syn,Rm} \left(1 - \frac{FR(N)}{IC_{50,Rm} + FR(N)} \right) - k_{deg}R_m \quad (1m)$$

$$\frac{dR_F}{dt} = k_{syn,R}R_m + r_f k_{re}FR(N) - k_{on}(F-1)R_F - k_{dgr,R}R_F \quad (1n)$$

$$\frac{dFR}{dt} = k_{on}FR_F - k_TFR \quad (1o)$$

$$\frac{dFR(N)}{dt} = k_T FR - k_{re} FR(N) \quad (1p)$$

This work has recently been extended to study the effects of endotoxemia on autonomic dysfunction (Foteinou et al. in press). The hormone epinephrine has been shown to modulate immune function (Padgett and Glaser, 2003). Epinephrine is secreted by the sympathetic nervous system (SNS), which is stimulated by the pro-inflammatory response (Elenkov et al., 2000) and ultimately leads to an increase in anti-inflammatory signaling, mediated by cAMP (van der Poll, 2001), as shown in Eq. (1q–t). Heart rate variability (HRV) is an important clinical marker for autonomic dysfunction. A decrease in HRV is one aspect of the diminished physiological variability caused by endotoxemia (Godin et al., 1996). HRV is incorporated into the model by a non-linear potentiation by pro-inflammatory activity in Eq. (1u–x).

$$\frac{dEPI}{dt} = k_{in,EPI}(1 + H_{EPI,P}) - k_{out,EPI}EPI \quad (1q)$$

$$\frac{dR_{EPI}}{dt} = k_{R_{EPI}}^0 - [k_{1,R_{EPI}}(1 + H_{R_{EPI},EPI}) + k_{2,R_{EPI}}]R_{EPI} \quad (1r)$$

$$\frac{dEPIR}{dt} = k_{1,R_{EPI}}(1 + H_{R_{EPI},EPI})R_{EPI} - k_{3,EPIR}(EPIR + 1) \quad (1s)$$

$$\frac{dcAMP}{dt} = \frac{1}{\tau}(EPIR^n - cAMP) \quad (1t)$$

$$\frac{df_p}{dt} = (1 + \tanh(P-w) - f_p)H_p \quad (1u)$$

$$\frac{dS_f}{dt} = \frac{1}{\tau_S}(H_p f_p^{n_S} - S_f) \quad (1v)$$

$$\frac{dHRV}{dt} = k_{in,HRV} - k_{out,HRV}(1 + k_{HRV,S}S_f)HRV \quad (1w)$$

$$H_p = \tanh(P^\phi - 1)^\phi \quad (1x)$$

Taken together, these elements in Eq. (1) comprise a semi-mechanistic model of human endotoxemia and its relationship to autonomic dysfunction. Further detail is available in previous publications (Foteinou et al. in press; Foteinou et al., 2009a; Foteinou et al., 2009b; Foteinou et al., 2009c).

2.2. Modeling circadian rhythms in inflammation

Many of the components described in the previous section are known to have circadian rhythms. Several studies have shown that numerous pro- and anti-inflammatory cytokines undergo diurnal variations in plasma levels, typically peaking in the night (Hermann et al., 2006; Petrovsky and Harrison, 1997; Petrovsky and Harrison, 1998; Petrovsky et al., 1998; Zabel et al., 1990). Plasma cortisol levels also exhibit a circadian pattern, peaking in the early morning. Cortisol is produced by the actions of the hypothalamic–pituitary–adrenal axis, and the circadian production is due to stimulation from the central circadian clock in the suprachiasmatic nucleus (SCN) (Hermann et al., 2006; Kohsaka and Bass, 2007).

Due to the immunomodulatory effects of glucocorticoids and the strong circadian pattern of plasma cortisol levels, cortisol has been implicated in the circadian entrainment of cytokine production (Petrovsky and Harrison, 1998). However, exogenous glucocorticoids administration is known to have a differential effect on cytokines; it stimulates the production of anti-inflammatory cytokines while inhibiting the production of pro-inflammatory cytokines (Barber et al., 1993; Barnes, 1998). Thus, it seems unlikely that cortisol alone could be responsible for the observed fluctuations in cytokine level, especially in light of the

fact that a number of other hormones also vary either in or out of phase with cytokine levels (Petrovsky and Harrison, 1998).

Of particular interest is the hormone melatonin, due to its potential role as a mediator in the crosstalk between the SCN and the immune system (Coogan and Wyse, 2008). Melatonin is tightly regulated to have a peak in production in the night while remaining at very low levels the rest of the day and it has been shown to stimulate the production of cytokines, likely through the melatonin receptors in human leukocytes (Guerrero and Reiter, 2002; Skwarlo-Sonta et al., 2003). This is supported by experimental evidence showing that pinealectomy leads to decreased cytokine production in mice (Delgobbo et al., 1989). Thus, in the model presented herein, melatonin is used as the primary circadian regulator of cytokine production. Melatonin and cortisol drive the circadian variation in all of the model variables.

In (Chakraborty et al., 1999), six different mathematical models are fit to experimental data to reproduce the circadian profile of plasma cortisol levels. They found that several of these models were adequately able to capture the dynamics of the cortisol profiles. To assess which circadian cortisol equation is most effective to incorporate into this multiscale model of inflammation, the different circadian cortisol models were tested and shown to produce qualitatively similar results. Ultimately, this work incorporates the “two rates” model due to its simplicity. In this model, a zero-order production term (RF) is set to two different values depending on the time of day and the circadian pattern is induced by using a high production rate in the morning and a low production rate the rest of the day (Eq. (2a)). For comparison, results for the most complex model, consisting of the first three terms of a Fourier series fit to the data (Eq. (2b)), are also shown.

$$\frac{dF}{dt} = RF + k_{in,F_{en}}(1 + H_{F_{en},P}) - k_{out,F}F$$

$$RF = \begin{cases} k_{in,RF1}, & t_{F1} < \text{mod}(t,24) < t_{F2} \\ 0 & t_{F2} < \text{mod}(t,24) < t_{F1} \end{cases} \quad (2a)$$

$$RF = a_0 + \sum_{n=1}^3 [a_n \cos(2\pi n t / 24) + b_n \sin(2\pi n t / 24)] \quad (2b)$$

Melatonin is modeled in a similar manner (Eq. (3)), using RM as a zero-order production term that is large during the night and small during the rest of the day and also including a first-order degradation term. More complex models of melatonin production are not investigated because melatonin levels do not have the type of biphasic pattern that is sometimes apparent for cortisol. However, it is well established that pro-inflammatory cytokines can reduce or even fully suppress the nocturnal peak in melatonin (Couto-Moraes et al., 2009; Fernandes et al., 2006; Jiang-Shieh et al., 2005; Pontes et al., 2006; Pontes et al., 2007; Skwarlo-Sonta et al., 2003) and corticosteroids can antagonize this effect by stimulating melatonin production (Fernandes et al., 2009; Fernandes et al., 2006; Ferreira et al., 2005). The indirect effect of these two substances on melatonin production is modeled by including an indirect stimulus term for cortisol and an indirect inhibition term for pro-inflammatory cytokines on the production rate of melatonin.

These models for cortisol and melatonin (Eqs. (2) and (3)) are fit to experimental data (Grivas and Savvidou, 2007; Hermann et al., 2006) to ensure that the peak levels of hormones in the model occur at the correct times.

$$\frac{dM}{dt} = RM \left(1 + \frac{F}{1+F} \right) \left(1 - \frac{P}{1+P} \right) - k_{out,RM}M$$

$$RM = \begin{cases} k_{in, RM1}, & t_{M1} < \text{mod}(t, 24) < t_{M2} \\ k_{in, RM2}, & t_{M2} < \text{mod}(t, 24) < t_{M1} \end{cases} \quad (3)$$

Melatonin has been shown to stimulate the production of both pro- and anti-inflammatory cytokines (Petrovsky and Harrison, 1997; Raghavendra et al., 2001). This is modeled by adding a stimulating term to the production rates of *P* and *A* (Eq. (4)). The strength of these interactions is calibrated based on experimental data for IL-1 α (*P*) (Petrovsky et al., 1998) and IL-10 (*A*) (Petrovsky and Harrison, 1997).

$$\frac{dP}{dt} = k_{in,P}(1 + H_{P,NFkB}) (1 + H_{P,E})(1 + H_{P,M})/A - k_{out,P}P \quad (4a)$$

$$\frac{dA}{dt} = k_{in,A}(1 + H_{A,CAMP})(1 + H_{A,E})(1 + H_{A,FRN})(1 + H_{A,M}) - k_{out,A}A \quad (4b)$$

Cortisol produced in the adrenal cortex directly interacts with the adrenal medulla, stimulating epinephrine production (Wurtman et al., 1972). This matches up well with available experimental data which shows that plasma epinephrine levels lag cortisol levels (Dimitrov et al., 2009; Kronfol et al., 1997). This is modeled by letting cortisol stimulate the production rate of epinephrine (Eq. (5a)). The normal circadian pattern of HRV is roughly sinusoidal with a peak in the night (Massin et al., 2000); this behavior is likely driven by sleep patterns and a decrease in sympathetic activity at night (Ewing et al., 1991). In this model, epinephrine is used as a surrogate for sympathetic activity, which inhibits the production rate of HRV. Experimental data are used to validate the responses of epinephrine (Kronfol et al., 1997) and HRV (Massin et al., 2000).

$$\frac{dEPI}{dt} = k_{in,EPI}(1 + H_{EPI,P})(1 + H_{EPI,FRN}) - k_{out,EPI}EPI \quad (5a)$$

$$\frac{dHRV}{dt} = k_{in,HRV}/EPI - k_{out,HRV}HRV \quad (5b)$$

It is difficult to draw precise, quantitative conclusions about specific levels of the variables in this model because often, experimental data is not sufficient to calibrate the model. For instance, the measurements of cytokines that are used are indirect measurements that only give relative levels of cytokines (Petrovsky and Harrison, 1997; Petrovsky et al., 1998). Thus, when plotted, all variables are scaled to be between 0 and 1 in the baseline case when there is no inflammatory stimulus (Fig. 2) by subtracting the minimum and dividing by the difference between the maximum and minimum. These scalings are then consistently used throughout the other figures.

All of the parameters used in the following simulations are shown in Table 1. After fitting the model to the data, sensitivity analysis is performed to gain insight into the model's dependence on the newly introduced parameters. As in (Ihekwwaba et al., 2004; Yue et al., 2006), for each parameter, the sensitivity coefficient is calculated as

$$S_p^m = \frac{\delta m/m}{\delta p/p} \quad (6)$$

where *p* represents the parameter that is varied, δp an incremental perturbation in the parameter, *m* the response of the original system, and δm the incremental change in *m* due to the perturbation δp . Then, *m* is defined as the minimum value of HRV, i.e. maximum HRV depression, throughout the entire time course in response to a low dose of LPS that result in a self-limited inflammatory response. Effectively, this sensitivity analysis measures how the perturbations in the parameter values affect the overall systemic response to the stimulus. Because this model responds differently depending on the time of dosing, due to the circadian nature of the baseline, the sensitivity analysis is run 24

different times to capture the response to LPS at the 24 different hours of the day.

3. Results

Eqs. (2–5), combined with the remaining unmodified equations from Eq. (1), comprise a model of human endotoxemia that takes into account circadian variations in most of its variables. A network diagram of these interactions is shown in Fig. 1. The model consists of several interacting modules representing various different scales; at the cellular level, the three essential transcriptional responses (pro-inflammatory *P*, anti-inflammatory *A*, and energetic *E*) are regulated by NFkB signaling and the recognition of LPS, as shown in the cellular level in Fig. 1. The circadian hormones section of Fig. 1 shows how the diurnal in the components of the system are driven by SCN-regulated circadian rhythms in cortisol and melatonin production. Interactions between peripheral inflammation and the neuroendocrine axis are accounted for by incorporating the inflammatory effects of the hormones cortisol, epinephrine, and melatonin along with the systemic level influences on heart rate variability.

The model is designed to reproduce experimental data from a variety of sources (Grivas and Savvidou, 2007; Hermann et al., 2006; Kronfol et al., 1997; Massin et al., 2000; Petrovsky and Harrison, 1997; Petrovsky et al., 1998), as shown in Fig. 2. In this figure, a simulation is run with no inflammatory stimulus, giving the normal baseline condition for the model variables. While there is a link between cortisol and the anti-inflammatory response, variations seen in both the pro- and anti-inflammatory responses are primarily driven by melatonin levels. Cortisol is responsible for modulating the production of epinephrine, resulting in epinephrine levels peaking during the day slightly after cortisol does. Then, HRV is inhibited by epinephrine levels.

In addition to the simple “two rates” model (Eq. (2a)) of cortisol used to generate Fig. 2, a more complex model based on the Fourier series (Eq. (2b)) was also tested as shown in Fig. 3. This model accounts for some of the small deviations from the simpler model, such as the small secondary peak after the diurnal decrease in cortisol levels is already underway. This allows for a better fit for the epinephrine data, which shows that the epinephrine levels increase faster than they decline. However, it also leads to a worse fit for HRV. Overall, the predictions do not qualitatively improve when using the more complex model in Fig. 3; thus, further results presented use the “two rates” model as in Fig. 2.

To determine the sensitivity of the system with respect to the parameters, sensitivity analysis is performed by calculating the sensitivity coefficient (Eq. (6)) for each parameter. The simulations are run for the case when the inflammatory stimulus is $LPS_0 = 1$, which leads to a self-limited inflammatory response, and the response is tested for dosing times at each of the 24 h of the day. Fig. 4 shows the results, with the large bars equal to the mean sensitivity coefficients and the small error bars equal to the standard deviation.

Fig. 5 shows simulations of the application of an identical large inflammatory stimulus ($LPS_0 = 10$) at two different times. First, at 8 am (dashed lines), cortisol levels are high while cytokine levels are low. Thus, the cytokines have less ability to initiate an inflammatory response, and they are countered by the anti-inflammatory influence of cortisol. When the inflammatory stimulus is given at 8 am, it provokes an acute response that resolves normally; within several hours, all of the variables have returned to their baseline values. But at midnight (solid lines), cortisol levels are very low and cytokine levels are high; thus, in this scenario, the system is more susceptible to inflammation.

Table 1
List of parameters used in the simulation of the model. Parameters 1–11 are the new parameters that were added to the previous model to incorporate the circadian effects. Parameters 12–64 are identical to those used in previous modeling efforts that did not account for diurnal variability. Many of the variables are dimensionless, so many of the parameters have units of either 1 or 1/h.

#	Parameter	Value	Units	Description
1	$k_{in,RM1}$	0.406	pg/mL/h	Production rate of M during the night
2	$k_{in,RM2}$	0.0318	pg/mL/h	Production rate of M during the day
3	$k_{out,RM}$	0.421	1/h	Clearance rate of M
4	$k_{in,F1}$	0.992	ng/mL/h	Circadian production rate of F
5	$k_{EPI,FRN}$	0.0901	mg L/nmol	Strength of indirect stimulus on EPI by $FR(N)$
6	$k_{P,M}$	0.973	mL/pg	Strength of indirect stimulus on P by M
7	$k_{A,M}$	1.00	mL/pg	Strength of indirect stimulus on A by M
8	T_{F1}	4.62	h	Start time for when cortisol production is heightened
9	T_{F2}	12.1	h	End time for when cortisol production is heightened
10	T_{M1}	21.9	h	Start time for when melatonin production is heightened
11	T_{M2}	1.73	h	End time for when melatonin production is heightened
12	$k_{in,A}$	0.461	1/h	Base production rate of A
13	$k_{A,cAMP}$	0.145	1	Strength of indirect stimulus on A by $cAMP$
14	$k_{A,E}$	0.534	1	Strength of indirect stimulus on A by E
15	$k_{out,A}$	0.810	1/h	Clearance rate of A
16	$k_{A,FRN}$	0.401	mg L/nmol	Strength of indirect stimulus on A by $FR(N)$
17	$k_{in,Fen}$	0.843	ng/mL/h	Base production rate of F
18	$k_{Fen,P}$	0.256	1	Strength of indirect stimulus on F by P
19	$k_{out,F}$	1.06	1/h	Clearance rate of F
20	$k_{in,EPI}$	5.92	pg/mL/h	Base production rate of EPI
21	$k_{EPI,P}$	0.231	1	Strength of indirect stimulus on EPI by P
22	$k_{out,EPI}$	7.29	1/h	Clearance rate of EPI
23	k_{REPI}^0	11.0	1/h	Production rate of $REPI$
24	$k_{1,REPI}$	3.01	1/h	Base binding rate between EPI and $REPI$
25	$k_{REPI,EPI}$	0.845	1	Stimulus on binding rate between EPI and $REPI$ by $REPI$
26	$k_{2,REPI}$	5.47	1/h	Clearance rate of $REPI$
27	$k_{3,EPIR}$	5.55	1/h	Dissociation rate between EPI and $REPI$
28	τ	0.0525	h	$cAMP$ mean transit time
29	η	5.51	1	$cAMP$ shaping factor
30	$k_{in,HRV}$	1.19	1	"Production rate" of HRV
31	$k_{out,HRV}$	1.05	1/h	"Clearance rate" of HRV
32	$k_{1ps,1}$	4.50	1/h	Growth rate of LPS
33	$k_{1ps,2}$	6.79	1/h	Clearance rate of LPS
34	k_{syn}	0.0200	1/h	Translation rate of R
35	k_2	0.0400	1/h	Dissociation rate between LPS and R
36	k_1	3.00	1/h	Binding rate between LPS and R
37	k_3	5.00	1/h	Decay rate of $LPSR$
38	k_4	2.24	1/h	Decay rate of IKK
39	$k_{in,mRNA,R}$	0.0914	1	Base transcription rate of $mRNA,R$
40	$k_{mRNA,R,P}$	1.74	1	Strength of indirect stimulus on $mRNA,R$ by P
41	$k_{out,mRNA,R}$	0.251	1/h	Decay rate of $mRNA,R$
42	$k_{NFKB,1}$	16.3	1/h	Base transport rate for $NFKB$ into the nucleus
43	$k_{NFKB,2}$	1.19	1/h	Base transport rate for $NFKB$ out of the nucleus
44	$k_{in,IkBa}$	0.463	1/h	Base transcription rate of $mRNA_{IkBa}$
45	$k_{IkBa,1}$	13.3	1	Strength of indirect stimulus on $mRNA_{IkBa}$ by $NFKBn$
46	$k_{out,IkBa}$	0.463	1/h	Decay rate of $mRNA_{IkBa}$
47	$k_{1,1}$	1.40	1/h	Translation rate of $IkBa$
48	$k_{1,2}$	0.870	1/h	Strength of indirect effects of IKK and $NFKBn$ on $IkBa$
49	$k_{in,P}$	0.0331	1/h	Base production rate of P
50	$k_{P,NFKBn}$	29.7	1	Strength of indirect stimulus on P by $NFKBn$
51	$k_{P,E}$	9.05	1	Strength of indirect stimulus on P by E
52	$k_{out,P}$	0.333	1/h	Decay rate of P
53	$k_{in,E}$	0.0800	1/h	Base production rate of E
54	$k_{E,P}$	2.210	1	Strength of indirect stimulus on E by P
55	$k_{out,E}$	0.257	1/h	Decay rate of E
56	$k_{syn,Rm}$	2.900	fmol/g/h	Base transcription rate of R_m
57	$IC_{50,Rm}$	26.2	nmol/L/mg	Concentration of $FR(N)$ producing half the maximum effect
58	k_{deg}	0.112	1/h	Decay rate of R_m
59	$k_{syn,R}$	1.12	1	Translation rate of R_f
60	T_f	0.490	1	Strength of stimulus on R_f by $FR(N)$
61	k_{re}	0.570	1/h	Transport rate of FR into the nucleus
62	k_{on}	0.00329	L/nmol/h	Binding rate between F and RF
63	$k_{dgr,R}$	0.0572	1/h	Decay rate of R_m
64	k_T	0.630	1/h	Transport rate of $FR(N)$ out of the nucleus

This is illustrated by the unresolved inflammatory response that is provoked by the inflammatory stimulus. Interestingly, even in the unresolved inflammatory state, the circadian oscillations persist in cortisol, epinephrine, and the pro- and anti-inflammatory

responses. These oscillations are in phase with the normal oscillations in Fig. 2.

Melatonin levels also respond differently in the two cases in Fig. 5. In the case when inflammation resolves (dashed lines),




Fig. 1. Network diagram of the components of the model.




Fig. 2. Simulation of the model when there is no inflammatory stimulus.

there is almost no change in melatonin relative to the normal conditions in Fig. 2. This is because the transient peaks in *P* and *A* occur during the day when melatonin levels are already low, so the cytokines cannot further suppress melatonin production. But in the case when inflammation does not resolve (solid lines), melatonin levels remain suppressed. However, a transient inflammatory response can still lead to a decrease in melatonin production, as shown in Fig. 6 when the inflammatory stimulus is given towards the beginning of the period when melatonin production is high.

The temporal variation in the inflammatory response to LPS is illustrated in Fig. 7. In this plot, the model is run as the time of the




Fig. 3. Simulation of the model, using an alternative equation for cortisol, when there is no inflammatory stimulus.

inflammatory stimulus ($LPS_0=1$) is varied. Then, the peak of the pro-inflammatory signal (P_{max}) is recorded as a representation of the overall strength of the inflammatory response. There is a significant diurnal variation in this signal, which peaks at night and is low during the daytime.

4. Discussion

Circadian rhythms are of critical importance in inflammation because so many of the biological components that regulate the outcome of inflammation are themselves under circadian regulation. This work presents the first model that incorporates the effect of circadian variability on the inflammatory response. Proper treatment of inflammatory diseases requires an appreciation of circadian effects (Hrushesky and Wood, 1997), so a quantitative understanding of diurnal variations on inflammation is important in efforts to translate computational systems biology approaches in inflammation to clinical relevance (Foteinou et al., 2009d; Vodovotz et al., 2008).

The sensitivity analysis shown in Fig. 4 illustrates the relative influence of the values of all model parameters on the outcome of the model. The outcome is defined as the minimum value of HRV after an inflammatory stimulus because heart rate variability is known to have prognostic value in critically ill patients. Because the sensitivity is measured with respect to changes in HRV, it is not surprising that some of the most sensitive parameters are in the equations for *EPI* ($k_{in,EPI}$ (20), $k_{out,EPI}$ (22) and k_{REPI}^0 (23)), which is closely linked to HRV in the model, and HRV itself ($k_{in,HRV}$ (30) and $k_{out,HRV}$ (31)). Parameters governing the behavior of both pro-inflammatory cytokines ($k_{in,P}$ (49), $k_{P,E}$ (51), and $k_{out,P}$ (52)) and anti-inflammatory cytokines ($k_{in,A}$ (12) and $k_{out,A}$ (15)) also have high sensitivities. Of the ten most sensitive parameters, eight represent the production and degradation terms for the four variables mentioned (HRV, *EPI*, *P*, and *A*). The other two are k_{REPI}^0 (23), the production rate of epinephrine's receptor, and $k_{P,E}$ (51), which links cellular energetic activity to changes in the pro-inflammatory response. Functionally, many of the most sensitive parameters relate to the communication between the different modules of the system. The acute inflammatory response relies on this signaling to activate other components of the neuroimmune system and provoke a systemic response to inflammation, and




Fig. 4. Sensitivity analysis on the model parameters. Sensitivity coefficients are calculated by using Eq. (6) with $\delta p = 0.01$. Error bars represent the standard deviation of the sensitivity coefficients for stimuli given at different times during the day. The numbered labels on the x-axis correspond to the parameters in Table 1.




Fig. 5. Simulation of the model for stimuli at two different times. An inflammatory stimulus is given at 8 am (dashed lines) or 12 am (solid lines). At 8 am, the system is able to recover from the inflammatory stimulus, but at 12 am, the same exact stimulus sends the system into an unresolved inflammatory state.

this is reflected by high sensitivities in parameters governing cytokine and hormonal signals.

The new parameters added to the model to account for circadian rhythms, labeled 1–11 in Fig. 4, have relatively low sensitivity coefficients compared to the most sensitive parameters from the original model that does not incorporate circadian effects, indicating that the model retains its diurnal response even when the new parameters are not precisely set. Yet although the sensitivities for the circadian parameters are less than the sensitivities of some of the other parameters mentioned earlier, this should not be taken to mean that the circadian components added to the model are unimportant in determining the outcome of the system. This is illustrated by the time-dependent responses found for identical inflammatory stimuli, as shown in Figs. 5–7.

The persistent inflammatory state shown in Fig. 5 (solid lines) is interesting because this type of persistent inflammation, either along with a persistent infection or after the pathogen is successfully cleared, has been observed clinically (Alberti et al., 2002; Bone, 1996). The suppression of the circadian release of

Fig. 6. The inflammatory response can suppress melatonin levels. The solid lines show an inflammatory response ($LPS_0=1$) initiated at 8 pm so that the inflammation is heightened when melatonin production is beginning to increase. The dashed lines show the baseline conditions (as in Fig. 2) for comparison. Pro-inflammatory cytokines suppress the production of melatonin, leading to suppressed nocturnal melatonin levels. However, normal melatonin production returns the following night when the pro-inflammatory signal has resolved.

melatonin, shown in the simulation in Fig. 6, illustrates the ability of the model to capture critical aspects of the neuroimmune feedback on the production of circadian hormones. A similar diminished nocturnal melatonin release in response to inflammation has been observed experimentally (Fernandes et al., 2006). Furthermore, the observed temporal dependence of the inflammatory response, as shown in Fig. 5 and 7, has important implications in translational medicine, where the goal is to translate current scientific discoveries into tools that can be applied to clinical problems. Specifically, modeling circadian variations in inflammation could lead to optimized clinical treatment times. Models could potentially be used to optimize the treatment of individual patients in an effort towards fulfilling the promise of personalized medicine. In inflammation, this is particularly important because it has been repeatedly observed that patients with sepsis have a significantly increased risk of mortality at night, but if they survive until the morning rise in




Fig. 7. Diurnal changes in the strength of the inflammatory response. The strength of the inflammatory response varies, as illustrated by monitoring either the maximal response of pro-inflammatory cytokines (P_{max}) or the maximum depression in HRV. Both of these variables have their maximum response in the night when normal levels of pro-inflammatory cytokines are elevated, and the minimum responses occur during the morning when cortisol levels are peaking.

cortisol levels is underway, they are likely to survive at least until the next night (Hrushesky and Wood, 1997). This qualitatively matches the results shown in Fig. 7, where the potential for an inflammatory response is greatest at night and is significantly lower during the daytime; furthermore, P_{max} reaches its minimum early in the morning when the risk of death from sepsis is decreased. The observed differences in P_{max} mainly arise due to the variations in cortisol and in both pro- and anti-inflammatory cytokines. When cortisol levels are high, the system is protected from a heightened inflammatory response. But when cortisol levels are low, natural variations in cytokine levels result in periods of time when the system is primed for an inflammatory response.

One key aspect of the interplay between circadian rhythms and inflammation that is not adequately considered in this work is the feedback from inflammation to circadian rhythms. There is some evidence suggesting that immune mediators can directly influence the circadian clock by modulating the strength of expression of clock-related genes and by shifting the phase of circadian rhythms (Coogan and Wyse, 2008). Melatonin has been implicated mediating these processes; additionally, inflammatory cytokines are known to influence the production of melatonin (Fernandes et al., 2006; Mundigler et al., 2002), likely facilitating bidirectional information transfer between the neuroendocrine and immune systems.

The relationship between circadian rhythms and inflammation may be of particular importance in understanding the effects of chronic stress. In response to chronic stress from a variety of stimuli, such as depression (Yehuda et al., 1996), obesity (Rosmond et al., 1998), psychological stress (Polk et al., 2005), and various types of cancer (Mormont and Levi, 1997), diurnal variations in plasma cortisol concentration are diminished while overall cortisol levels remain high. The loss of the circadian nature of autonomic and neuroendocrine signaling in chronically stressed patients may be linked to a patient's overall potential to mount a healthy response to an inflammatory stressor (Lowry, 2009). Furthermore, an extended period of stress hormone exposure results in diminished anti-inflammatory capacity as manifested by dynamic alterations in circulating levels of the anti-inflammatory cytokine IL-10, similar to subjects exposed

only to LPS (van der Poll et al., 1996a; van der Poll et al., 1996b). The clinical relevance of the circadian component of inflammation, particularly as it relates to chronic stress, is illustrated by the fact that diminished diurnal variability in cortisol is associated with increased mortality in patients with breast cancer (Sephton et al., 2000). The model presented here provides a solid foundation towards future work exploring the intricacies of these interactions.

Acknowledgements

JDS and IPA acknowledge support from NIH GM082974. JDS, SEC and SFL are supported, in part, from NIH GM34695.

References

- Alberti, C., Brun-Buisson, C., Burchardi, H., Martin, C., Goodman, S., Artigas, A., Sicignano, A., Palazzo, M., Moreno, R., Boulme, R., Lepage, E., Le Gall, J.R., 2002. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Medicine* 28 (2), 108–121.
- Aldridge, B.B., Burke, J.M., Lauffenburger, D.A., Sorger, P.K., 2006. Physicochemical modelling of cell signalling pathways. *Nature Cell Biology* 8 (11), 1195–1203.
- An, G., 2008. Introduction of an agent-based multi-scale modular architecture for dynamic knowledge representation of acute inflammation. *Theoretical Biology and Medical Modelling* 5, 11.
- Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Critical Care Medicine* 29 (7), 1303–1310.
- Anname, D., Sebille, V., Charpentier, C., Bollaert, P.E., Francois, B., Korach, J.M., Capellier, G., Cohen, Y., Azoulay, E., Troche, G., Chaumet-Riffaut, P., Bellissant, E., 2002. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *Jama—Journal of the American Medical Association* 288 (7), 862–871.
- Barber, A.E., Coyle, S.M., Marano, M.A., Fischer, E., Calvano, S.E., Fong, Y.M., Moldawer, L.L., Lowry, S.F., 1993. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. *Journal of Immunology* 150 (5), 1999–2006.
- Barnes, P.J., 1998. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clinical Science* 94 (6), 557–572.
- Bernard, G.R., Vincent, J.L., Laterre, P., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., Fisher, C.J., 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. *New England Journal of Medicine* 344 (10), 699–709.
- Bone, R.C., 1996. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). *Annals of Internal Medicine* 125 (8), 680–687.
- Chakraborty, A., Krzyzanski, W., Jusko, W.J., 1999. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. *Journal of Pharmacokinetics and Biopharmaceutics* 27 (1), 23–43.
- Clermont, G., Bartels, J., Kumar, R., Constantine, G., Vodovotz, Y., Chow, C., 2004. In silico design of clinical trials: a method coming of age. *Critical Care Medicine* 32 (10), 2061–2070.
- Coogan, A.N., Wyse, C.A., 2008. Neuroimmunology of the circadian clock. *Brain Research* 1232, 104–112.
- Couto-Moraes, R., Palermo-Neto, J., Markus, R.P., 2009. The immune-pineal axis stress as a modulator of pineal gland function. *Neuroimmunomodulation: From Fundamental Biology to Therapy* 1153, 193–202.
- Delgobbo, V., Libri, V., Villani, N., Calio, R., Nistico, G., 1989. Pinelectomy inhibits interleukin-2 production and natural-killer activity in mice. *International Journal of Immunopharmacology* 11 (5), 567–573.
- Dimitrov, S., Benedict, C., Heutling, D., Westermann, J., Born, J., Lange, T., 2009. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. *Blood* 113 (21), 5134–5143.
- Elenkov, I.J., Wilder, R.L., Chrousos, G.P., Vizi, E.S., 2000. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. *Pharmacological Reviews* 52 (4), 595–638.
- Ewing, D.J., Neilson, J.M., Shapiro, C.M., Stewart, J.A., Reid, W., 1991. Twenty four hour heart rate variability: effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients. *British Heart Journal* 65 (5), 239–244.
- Fernandes, P., Bothorel, B., Clesse, D., Monteiro, A.W.A., Calgari, C., Raison, S., Simonneaux, V., Markus, R.P., 2009. Local corticosterone infusion enhances nocturnal pineal melatonin production in vivo. *Journal of Neuroendocrinology* 21 (2), 90–97.
- Fernandes, P., Cecon, E., Markus, R.P., Ferreira, Z.S., 2006. Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of

- the immune response on circadian timing. *Journal of Pineal Research* 41 (4), 344–350.
- Ferreira, Z.S., Fernandes, P., Duma, D., Assrey, J., Avellar, M.C.W., Markus, R.P., 2005. Corticosterone modulates noradrenaline-induced melatonin synthesis through inhibition of nuclear factor kappa B. *Journal of Pineal Research* 38 (3), 182–188.
- Foteinou, P.T., Calvano, S.E., Lowry, S.F., Androulakis, I.P., A Multi-scale model for the assessment of autonomic dysfunction in human endotoxemia. *Physiological Genomics* in press, <doi:10.1152/physiolgenomics.00184.2009>.
- Foteinou, P.T., Calvano, S.E., Lowry, S.F., Androulakis, I.P., 2009a. In silico simulation of corticosteroids effect on an NFkB-dependent physicochemical model of systemic inflammation. *PLoS ONE* 4 (3), e4706.
- Foteinou, P.T., Calvano, S.E., Lowry, S.F., Androulakis, I.P., 2009b. Modeling endotoxin-induced systemic inflammation using an indirect response approach. *Mathematical Biosciences* 217 (1), 27–42.
- Foteinou, P.T., Calvano, S.E., Lowry, S.F., Androulakis, I.P., 2009c. A multiscale model for the assessment of autonomic dysfunction in human endotoxemia. *Journal of Critical Care* 24 (3), e25.
- Foteinou, P.T., Calvano, S.E., Lowry, S.F., Androulakis, I.P., 2009d. Translational potential of systems-based models of inflammation. *Clinical and Translational Science* 2 (1), 85–89.
- Freeman, B.D., Natanson, C., 2000. Anti-inflammatory therapies in sepsis and septic shock. *Expert Opinion on Investigational Drugs* 9 (7), 1651–1663.
- Godin, P.J., Fleisher, L.A., Eidsath, A., Vandivier, R.W., Preas, H.L., Banks, S.M., Buchman, T.G., Suffredini, A.F., 1996. Experimental human endotoxemia increases cardiac regularity: results from a prospective, randomized, crossover trial. *Critical Care Medicine* 24 (7), 1117–1124.
- Grivas, T.B., Savvidou, O.D., 2007. Melatonin the “light of night” in human biology and adolescent idiopathic scoliosis. *Scoliosis* 2, 6.
- Guerrero, J.M., Reiter, R.J., 2002. Melatonin-immune system relationships. *Current Topics in Medicinal Chemistry* 2 (2), 167–179.
- Hermann, C., von Aulock, S., Dehus, O., Keller, M., Okigami, H., Gantner, F., Wendel, A., Hartung, T., 2006. Endogenous cortisol determines the circadian rhythm of lipopolysaccharide but not lipoteichoic acid-inducible cytokine release. *European Journal of Immunology* 36 (2), 371–379.
- Hrushesky, W.J.M., Langevin, T., Kim, Y.J., Wood, P.A., 1994. Circadian dynamics of tumor-necrosis-factor-alpha (Cachectin) lethality. *Journal of Experimental Medicine* 180 (3), 1059–1065.
- Hrushesky, W.J.M., Wood, P.A., 1997. Circadian time structure of septic shock: timing is everything. *Journal of Infectious Diseases* 175 (5), 1283–1284.
- Ihekwa, A.E., Broomhead, D.S., Grimley, R.L., Benson, N., Kell, D.B., 2004. Sensitivity analysis of parameters controlling oscillatory signalling in the NF-kappa B pathway: the roles of IKK and I kappa B alpha. *Systems Biology* 1 (1), 93–103.
- Jiang-Shieh, Y.F., Wu, C.H., Chien, H.F., Wei, I.H., Chang, M.L., Shieh, J.Y., Wen, C.Y., 2005. Reactive changes of interstitial glia and pinealocytes in the rat pineal gland challenged with cell wall components from gram-positive and -negative bacteria. *Journal of Pineal Research* 38 (1), 17–26.
- Jit, M., Henderson, B., Stevens, M., Seymour, R.M., 2005. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. *Rheumatology* 44 (3), 323–331.
- Jusko, W.J., Ko, H.C., 1994. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. *Clinical Pharmacology and Therapeutics* 56 (4), 406–419.
- Kohsaka, A., Bass, J., 2007. A sense of time: how molecular clocks organize metabolism. *Trends in Endocrinology and Metabolism* 18 (1), 4–11.
- Kronfol, Z., Nair, M., Zhang, Q., Hill, E.E., Brown, M.B., 1997. Circadian immune measures in healthy volunteers: Relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. *Psychosomatic Medicine* 59 (1), 42–50.
- Kumar, R., Chow, C.C., Bartels, J.D., Clermont, G., Vodovotz, Y., 2008. A mathematical simulation of the inflammatory response to anthrax infection. *Shock* 29 (1), 104–111.
- Levi, F., Schibler, U., 2007. Circadian rhythms: mechanisms and therapeutic implications. *Annual Review of Pharmacology and Toxicology* 47, 593–628.
- Li, N.Y.K., Verdolini, K., Clermont, G., Mi, Q., Rubinstein, E.N., Hebda, P.A., Vodovotz, Y., 2008. A patient-specific in silico model of inflammation and healing tested in acute vocal fold injury. *PLoS ONE* 3 (7), e2789.
- Lipniacki, T., Paszek, P., Brasier, A.R., Luxon, B.A., Kimmel, M., 2006. Stochastic regulation in early immune response. *Biophysical Journal* 90 (3), 725–742.
- Lowry, S.F., 2005. Human endotoxemia: a model for mechanistic insight and therapeutic targeting. *Shock* 24, 94–100.
- Lowry, S.F., 2009. The stressed host response to infection: the disruptive signals and rhythms of systemic inflammation. *Surgical Clinics of North America* 89 (2), 311.
- Massin, M.M., Maeys, K., Withofs, N., Ravet, F., Gerard, P., 2000. Circadian rhythm of heart rate and heart rate variability. *Archives of Disease in Childhood* 83 (2), 179–182.
- Mi, Q., Rivière, B., Clermont, G., Steed, D.L., Vodovotz, Y., 2007. Agent-based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor-1. *Wound Repair and Regeneration* 15 (5), 671–682.
- Mormont, M.C., Levi, F., 1997. Circadian-system alterations during cancer processes: a review. *International Journal of Cancer* 70 (2), 241–247.
- Mundigler, G., Delle-Karth, G., Koreny, M., Zehetgruber, M., Steindl-Munda, P., Marktl, W., Fertl, L., Siostrzonek, P., 2002. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. *Critical Care Medicine* 30 (3), 536–540.
- Padgett, D.A., Glaser, R., 2003. How stress influences the immune response. *Trends in Immunology* 24 (8), 444–448.
- Petrovsky, N., Harrison, L.C., 1997. Diurnal rhythmicity of human cytokine production—A dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? *Journal of Immunology* 158 (11) 5163–5168.
- Petrovsky, N., Harrison, L.C., 1998. The chronobiology of human cytokine production. *International Reviews of Immunology* 16 (5–6), 635–649.
- Petrovsky, N., McNair, P., Harrison, L.C., 1998. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. *Cytokine* 10 (4), 307–312.
- Polk, D.E., Cohen, S., Doyle, W.J., Skoner, D.P., Kirschbaum, C., 2005. State and trait affect as predictors of salivary cortisol in healthy adults. *Psychoneuroendocrinology* 30 (3), 261–272.
- Pontes, G.N., Cardoso, E.C., Carneiro-Sampaio, M.M.S., Markus, R.P., 2006. Injury switches melatonin production source from endocrine (pineal) to paracrine (phagocytes)-melatonin in human colostrum and colostrum phagocytes. *Journal of Pineal Research* 41 (2), 136–141.
- Pontes, G.N., Cardoso, E.C., Carneiro-Sampaio, M.M.S., Markus, R.P., 2007. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. *Journal of Pineal Research* 43 (4), 365–371.
- Prince, J.M., Levy, R.M., Bartels, J., Baratt, A., Kane, J.M., Lagoa, C., Rubin, J., Day, J., Wei, J., Fink, M.P., Goyert, S.M., Clermont, G., Billiar, T.R., Vodovotz, Y., 2006. In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. *Molecular Medicine* 12 (4–6), 88–96.
- Raghavendra, V., Singh, V., Kulkarni, S.K., Agrewala, J.N., 2001. Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. *Molecular and Cellular Biochemistry* 221 (1–2), 57–62.
- Rosmond, R., Dallman, M.F., Bjornorp, P., 1998. Stress-related cortisol secretion in men: Relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. *Journal of Clinical Endocrinology and Metabolism* 83 (6), 1853–1859.
- Seely, A.J.E., Christou, N.V., 2000. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. *Critical Care Medicine* 28 (7), 2193–2200.
- Sephton, S.E., Sapolsky, R.M., Kraemer, H.C., Spiegel, D., 2000. Diurnal cortisol rhythm as a predictor of breast cancer survival. *Journal of the National Cancer Institute* 92 (12), 994–1000.
- Skwarlo-Sonta, K., Majewski, P., Markowska, M., Oblap, R., Olszanska, B., 2003. Bidirectional communication between the pineal gland and the immune system. *Canadian Journal of Physiology and Pharmacology* 81 (4), 342–349.
- van der Poll, T., 2001. Effects of catecholamines on the inflammatory response. *Sepsis* 4 (2), 159–167.
- van der Poll, T., Barber, A.E., Coyle, S.M., Lowry, S.F., 1996a. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia—A clinical research center study. *Journal of Clinical Endocrinology and Metabolism* 81 (10), 3604–3606.
- van der Poll, T., Coyle, S.M., Barbosa, K., Braxton, C.C., Lowry, S.F., 1996b. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. *Journal of Clinical Investigation* 97 (3), 713–719.
- Vodovotz, Y., Clermont, G., Chow, C., An, G., 2004. Mathematical models of the acute inflammatory response. *Current Opinion in Critical Care* 10 (5), 383–390.
- Vodovotz, Y., Csete, M., Bartels, J., Chang, S., An, G., 2008. Translational systems biology of inflammation. *PLoS Computational Biology* 4 (4).
- Wurtman, R.J., Pohorecky, L.A., Baliga, B.S., 1972. Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. *Pharmacological Reviews* 24 (2), 411–426.
- Yang, E.H., Almon, R.R., DuBois, D.C., Jusko, W.J., Androulakis, I.P., 2009. Identification of global transcriptional dynamics. *PLoS ONE* 4 (7), e5992.
- Yehuda, R., Teicher, M.H., Trestman, R.L., Levengood, R.A., Siever, L.J., 1996. Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis. *Biological Psychiatry* 40 (2), 79–88.
- Yue, H., Brown, M., Knowles, J., Wang, H., Broomhead, D.S., Kell, D.B., 2006. Insights into the behaviour of systems biology models from dynamic sensitivity and identifiability analysis: a case study of an NF-kappa B signalling pathway. *Molecular Biosystems* 2 (12), 640–649.
- Zabel, P., Horst, H.J., Kreiker, C., Schlaak, M., 1990. Circadian rhythm of interleukin-1 production of monocytes and the influence of endogenous and exogenous glucocorticoids in man. *Klinische Wochenschrift* 68 (24), 1217–1221.
- Zuev, S.M., Kingsmore, S.F., Gessler, D.D.G., 2006. Sepsis progression and outcome: a dynamical model. *Theoretical Biology and Medical Modelling* 3, 8.